Literature DB >> 12800950

Hepatitis C virus infection in Lebanese patients with B-cell non-Hodgkin's lymphoma.

Z Salem1, N Nuwaiyri-Salti, F Ramlawi, S Ramia.   

Abstract

Several studies from many countries have reported a high prevalence (> 9%) of hepatitis C virus (HCV) infection in patients with B-cell non-Hodgkin lymphoma (B-NHL) suggesting a possible etiological role of HCV in the development of B-NHL. Data from the United Kingdom and Turkey, however, did not confirm these observations. To determine the prevalence of HCV infection in patients with B-cell lymphoma in Lebanon, a controlled study was conducted in which 318 Lebanese patients were investigated. These included 35 patients with B-NHL, 63 patients with various malignant conditions (control group 1) and 220 patients with non-malignant conditions (control group 2). Samples were tested in duplicates for antibodies to HCV (anti-HCV) by enzyme-linked immunosorbant assay (ELISA). None of the 318 patients investigated were anti-HCV positive. Based on our findings, it can be concluded, that, there is no sufficient evidence to indicate that HCV plays role in the development of B-NHL in Lebanese patients. Predisposing factors in lymphoproliferative disorders are numerous including both genetic and environmental factors that could vary from one geographic region to another.

Entities:  

Mesh:

Year:  2003        PMID: 12800950     DOI: 10.1023/A:1023380316098

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  23 in total

1.  Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma.

Authors:  E Zuckerman; T Zuckerman; A M Levine; D Douer; K Gutekunst; M Mizokami; D G Qian; M Velankar; B N Nathwani; T L Fong
Journal:  Ann Intern Med       Date:  1997-09-15       Impact factor: 25.391

2.  Non-Hodgkin's lymphoma and hepatitis C virus infection.

Authors:  A M Brind; J P Watson; A Burt; P Kestevan; J Wallis; S J Proctor; M F Bassendine
Journal:  Leuk Lymphoma       Date:  1996-03

3.  Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV).

Authors:  U Hopf; B Möller; D Küther; R Stemerowicz; H Lobeck; A Lüdtke-Handjery; E Walter; H E Blum; M Roggendorf; F Deinhardt
Journal:  J Hepatol       Date:  1990-01       Impact factor: 25.083

4.  Hepatitis C virus infection in non-Hodgkin's B-cell lymphoma complicating mixed cryoglobulinaemia.

Authors:  C Ferri; M Monti; L La Civita; G Careccia; C Mazzaro; G Longombardo; F Lombardini; F Greco; G Pasero; S Bombardieri
Journal:  Eur J Clin Invest       Date:  1994-11       Impact factor: 4.686

5.  Sequence analysis of the putative structural genes of hepatitis C virus from Japanese and European origin.

Authors:  A M Delisse; M Descurieux; T Rutgers; E D'Hondt; M De Wilde; T Arima; J M Barrera-Sala; M G Ercilla; J L Ruelle; T Cabezon
Journal:  J Hepatol       Date:  1991       Impact factor: 25.083

6.  Prevalence of hepatitis-G virus and hepatitis-C virus infection in patients with non-Hodgkin's lymphoma.

Authors:  A Arican; T Sengezer; M Bozdayi; H Bozkaya; E Uçgül; D Dinçol; O Uzunalimoğlu
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

7.  [Hepatitis C virus in hemodialysis patients and blood donors in Lebanon].

Authors:  R E Naman; I Mansour; S Klayme; G Khalil
Journal:  J Med Liban       Date:  1996

8.  HCV and non-Hodgkin lymphoma.

Authors:  P Pioltelli; G Zehender; G Monti; A Monteverde; M Galli
Journal:  Lancet       Date:  1996-03-02       Impact factor: 79.321

9.  Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study.

Authors:  S Bellentani; C Tiribelli; G Saccoccio; M Sodde; N Fratti; C De Martin; G Cristianini
Journal:  Hepatology       Date:  1994-12       Impact factor: 17.425

10.  Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders.

Authors:  F Silvestri; C Pipan; G Barillari; F Zaja; R Fanin; L Infanti; D Russo; E Falasca; G A Botta; M Baccarani
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

View more
  4 in total

1.  Risk of malignant lymphoma following viral hepatitis infection.

Authors:  Pierluigi Cocco; Giovanna Piras; Maria Monne; Antonella Uras; Attilio Gabbas; Maria G Ennas; Angelo Palmas; Marco Murineddu; Stefania Collu; Massimo Melis; Marco Rais; Pierfelice Todde; Maria G Cabras; Emanuele Angelucci; Giovannino Massarelli; Alexandra Nieters
Journal:  Int J Hematol       Date:  2008-05-01       Impact factor: 2.490

2.  A collaborative nationwide lymphoma study in Lebanon: incidence of various subtypes and analysis of associations with viruses.

Authors:  Zaher K Otrock; Jad Saab; Georges Aftimos; Fady Nasr; Fadi S Farhat; Saad Khairallah; Gérard Abadjian; Marwan Ghosn; Hassan Sidani; Ahmad Ibrahim; Ayman Tawil; Claude Ghorra; Zarouhie Meguerian; Walid Mokaddem; Walid Dayeh; Ziad Salem; Georges Chahine; Nizar Bitar; Anas Mugharbel; Joseph Makdessi; Christina Khater; Mirna El Hajj; Dany Abi Gerges; Charles Sfeir; Joseph Kattan; Khaled Ibrahim; Michel Saade; Hussein Sadek; Rami A Mahfouz; Mohamed A Kharfan-Dabaja; Ghazi Zaatari; Ali Bazarbachi
Journal:  Pathol Oncol Res       Date:  2013-05-08       Impact factor: 3.201

Review 3.  Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: A systematic review.

Authors:  Sirio Fiorino; Letizia Bacchi-Reggiani; Dario de Biase; Adele Fornelli; Michele Masetti; Andrea Tura; Fabio Grizzi; Matteo Zanello; Laura Mastrangelo; Raffaele Lombardi; Giorgia Acquaviva; Luca di Tommaso; Arrigo Bondi; Michela Visani; Sergio Sabbatani; Laura Pontoriero; Carlo Fabbri; Andrea Cuppini; Annalisa Pession; Elio Jovine
Journal:  World J Gastroenterol       Date:  2015-12-07       Impact factor: 5.742

Review 4.  The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis.

Authors:  Hiam Chemaitelly; Karima Chaabna; Laith J Abu-Raddad
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.